http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 16:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+29/26583347.html si-local-file:///var/storage/secattach/20260601/26583347.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+29/26583347.html Mon, 01 Jun 2026 16:03:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+29/26583347.html si-local-file:///var/storage/secattach/20260601/26583347.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+29/26583347.html Mon, 01 Jun 2026 16:03:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Kiselak+Tomas/26576821.html si-local-file:///var/storage/secattach/20260529/26576821.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Kiselak+Tomas/26576821.html Fri, 29 May 2026 17:58:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Kiselak+Tomas/26576821.html si-local-file:///var/storage/secattach/20260529/26576821.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Kiselak+Tomas/26576821.html Fri, 29 May 2026 17:58:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+HENDERSON+MICHAEL+THOMAS/26576815.html si-local-file:///var/storage/secattach/20260529/26576815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+HENDERSON+MICHAEL+THOMAS/26576815.html Fri, 29 May 2026 17:56:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+HENDERSON+MICHAEL+THOMAS/26576815.html si-local-file:///var/storage/secattach/20260529/26576815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+HENDERSON+MICHAEL+THOMAS/26576815.html Fri, 29 May 2026 17:56:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Albers+Jeffrey+W./26576817.html si-local-file:///var/storage/secattach/20260529/26576817.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Albers+Jeffrey+W./26576817.html Fri, 29 May 2026 17:56:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Albers+Jeffrey+W./26576817.html si-local-file:///var/storage/secattach/20260529/26576817.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Albers+Jeffrey+W./26576817.html Fri, 29 May 2026 17:56:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Milligan+Sandra/26576812.html si-local-file:///var/storage/secattach/20260529/26576812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Milligan+Sandra/26576812.html Fri, 29 May 2026 17:55:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Milligan+Sandra/26576812.html si-local-file:///var/storage/secattach/20260529/26576812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Milligan+Sandra/26576812.html Fri, 29 May 2026 17:55:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+McKenna+Mark+C./26576813.html si-local-file:///var/storage/secattach/20260529/26576813.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+McKenna+Mark+C./26576813.html Fri, 29 May 2026 17:55:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+McKenna+Mark+C./26576813.html si-local-file:///var/storage/secattach/20260529/26576813.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+McKenna+Mark+C./26576813.html Fri, 29 May 2026 17:55:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Stelzer+Laurie/26576814.html si-local-file:///var/storage/secattach/20260529/26576814.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Stelzer+Laurie/26576814.html Fri, 29 May 2026 17:55:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Stelzer+Laurie/26576814.html si-local-file:///var/storage/secattach/20260529/26576814.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27++Filed+by%3A+Stelzer+Laurie/26576814.html Fri, 29 May 2026 17:55:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27/26576082.html si-local-file:///var/storage/secattach/20260529/26576082.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27/26576082.html Fri, 29 May 2026 16:46:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27/26576082.html si-local-file:///var/storage/secattach/20260529/26576082.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+27/26576082.html Fri, 29 May 2026 16:46:00 -0400 O.25515888 SYRE http://www.streetinsider.com/Press+Releases/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html <p>DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=f8meBfWUhXZQP-yRbvBQLjTvn6ASGivCtnewik8yBzHKkxblwL6qjeY5MB5Af85zSFN8fOcPcTliRDpUVfYvgHxVD4Cl2ApizYKR5QYzCRk=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.</p> <p>Download the 24/7 Market News App here <a href="https://www.globenewswire.com/Tracker?data=AqHBTtM71FArofWNsaJFzr5cZTakMRkqJJgf8DxEUsvrugfSOwMlLKzgh1cZ7-pATwm4A-pBovMhlxlN99mYEsLqK_XLGIb8lrDncN5mZOc=" rel="nofollow" target="_blank"><u>https://app.247mnn.com/</u></a> or on the App Store</p> <p>That is why so much attention is focused on companies that are approaching http://www.streetinsider.com/Press+Releases/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html Thu, 28 May 2026 08:35:00 -0400 ABVX ORKA SYRE http://www.streetinsider.com/Press+Releases/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html <p>DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=f8meBfWUhXZQP-yRbvBQLjTvn6ASGivCtnewik8yBzHKkxblwL6qjeY5MB5Af85zSFN8fOcPcTliRDpUVfYvgHxVD4Cl2ApizYKR5QYzCRk=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.</p> <p>Download the 24/7 Market News App here <a href="https://www.globenewswire.com/Tracker?data=AqHBTtM71FArofWNsaJFzr5cZTakMRkqJJgf8DxEUsvrugfSOwMlLKzgh1cZ7-pATwm4A-pBovMhlxlN99mYEsLqK_XLGIb8lrDncN5mZOc=" rel="nofollow" target="_blank"><u>https://app.247mnn.com/</u></a> or on the App Store</p> <p>That is why so much attention is focused on companies that are approaching http://www.streetinsider.com/Press+Releases/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html Thu, 28 May 2026 08:35:00 -0400 ABVX ORKA SYRE http://www.streetinsider.com/Press+Releases/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html <p>DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=f8meBfWUhXZQP-yRbvBQLjTvn6ASGivCtnewik8yBzHKkxblwL6qjeY5MB5Af85zSFN8fOcPcTliRDpUVfYvgHxVD4Cl2ApizYKR5QYzCRk=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.</p> <p>Download the 24/7 Market News App here <a href="https://www.globenewswire.com/Tracker?data=AqHBTtM71FArofWNsaJFzr5cZTakMRkqJJgf8DxEUsvrugfSOwMlLKzgh1cZ7-pATwm4A-pBovMhlxlN99mYEsLqK_XLGIb8lrDncN5mZOc=" rel="nofollow" target="_blank"><u>https://app.247mnn.com/</u></a> or on the App Store</p> <p>That is why so much attention is focused on companies that are approaching http://www.streetinsider.com/Press+Releases/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html Thu, 28 May 2026 08:35:00 -0400 ABVX ORKA SYRE http://www.streetinsider.com/Globe+Newswire/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html <p>DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=f8meBfWUhXZQP-yRbvBQLjTvn6ASGivCtnewik8yBzHKkxblwL6qjeY5MB5Af85zSFN8fOcPcTliRDpUVfYvgHxVD4Cl2ApizYKR5QYzCRk=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.</p> <p>Download the 24/7 Market News App here <a href="https://www.globenewswire.com/Tracker?data=AqHBTtM71FArofWNsaJFzr5cZTakMRkqJJgf8DxEUsvrugfSOwMlLKzgh1cZ7-pATwm4A-pBovMhlxlN99mYEsLqK_XLGIb8lrDncN5mZOc=" rel="nofollow" target="_blank"><u>https://app.247mnn.com/</u></a> or on the App Store</p> <p>That is why so much attention is focused on companies that are approaching http://www.streetinsider.com/Globe+Newswire/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html Thu, 28 May 2026 08:35:00 -0400 ABVX ORKA SYRE http://www.streetinsider.com/Globe+Newswire/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html <p>DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=f8meBfWUhXZQP-yRbvBQLjTvn6ASGivCtnewik8yBzHKkxblwL6qjeY5MB5Af85zSFN8fOcPcTliRDpUVfYvgHxVD4Cl2ApizYKR5QYzCRk=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.</p> <p>Download the 24/7 Market News App here <a href="https://www.globenewswire.com/Tracker?data=AqHBTtM71FArofWNsaJFzr5cZTakMRkqJJgf8DxEUsvrugfSOwMlLKzgh1cZ7-pATwm4A-pBovMhlxlN99mYEsLqK_XLGIb8lrDncN5mZOc=" rel="nofollow" target="_blank"><u>https://app.247mnn.com/</u></a> or on the App Store</p> <p>That is why so much attention is focused on companies that are approaching http://www.streetinsider.com/Globe+Newswire/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html Thu, 28 May 2026 08:35:00 -0400 ABVX ORKA SYRE http://www.streetinsider.com/Globe+Newswire/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html <p>DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=f8meBfWUhXZQP-yRbvBQLjTvn6ASGivCtnewik8yBzHKkxblwL6qjeY5MB5Af85zSFN8fOcPcTliRDpUVfYvgHxVD4Cl2ApizYKR5QYzCRk=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts.</p> <p>Download the 24/7 Market News App here <a href="https://www.globenewswire.com/Tracker?data=AqHBTtM71FArofWNsaJFzr5cZTakMRkqJJgf8DxEUsvrugfSOwMlLKzgh1cZ7-pATwm4A-pBovMhlxlN99mYEsLqK_XLGIb8lrDncN5mZOc=" rel="nofollow" target="_blank"><u>https://app.247mnn.com/</u></a> or on the App Store</p> <p>That is why so much attention is focused on companies that are approaching http://www.streetinsider.com/Globe+Newswire/Phase+2+Data+could+Transform+these+Biotechs+from+Clinical+Promise+to+Market+Validation/26561844.html Thu, 28 May 2026 08:35:00 -0400 ABVX ORKA SYRE http://www.streetinsider.com/Press+Releases/Spyre+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26549768.html <p>WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong><u>Event</u></strong><strong>: Jefferies Global Healthcare Conference – New York</strong><br /><strong><u>Date:</u></strong> Wednesday, June 3, 2026<br /><strong><u>Fireside Time:</u></strong> 12:15 pm ET</p> <p><strong><u>Event:</u></strong><strong> Goldman Sachs 47</strong>^{<strong>th</strong>}<strong> Annual Global Healthcare Conference – Miami</strong><br /><strong><u>Date:</u></strong> Monday, June 8, 2026<br /><strong><u>Fireside Time:</u></strong> 10:00 am ET</p> <p>Members of the Spyre management team will also http://www.streetinsider.com/Press+Releases/Spyre+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26549768.html Tue, 26 May 2026 16:10:00 -0400 SYRE http://www.streetinsider.com/Globe+Newswire/Spyre+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26549768.html <p>WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong><u>Event</u></strong><strong>: Jefferies Global Healthcare Conference – New York</strong><br /><strong><u>Date:</u></strong> Wednesday, June 3, 2026<br /><strong><u>Fireside Time:</u></strong> 12:15 pm ET</p> <p><strong><u>Event:</u></strong><strong> Goldman Sachs 47</strong>^{<strong>th</strong>}<strong> Annual Global Healthcare Conference – Miami</strong><br /><strong><u>Date:</u></strong> Monday, June 8, 2026<br /><strong><u>Fireside Time:</u></strong> 10:00 am ET</p> <p>Members of the Spyre management team will also http://www.streetinsider.com/Globe+Newswire/Spyre+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26549768.html Tue, 26 May 2026 16:10:00 -0400 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+08++Filed+by%3A+HENDERSON+MICHAEL+THOMAS/26463120.html si-local-file:///var/storage/secattach/20260508/26463120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+May+08++Filed+by%3A+HENDERSON+MICHAEL+THOMAS/26463120.html Fri, 08 May 2026 21:32:00 -0400 O.25515888 SYRE